SOLARIS THERAPEUTICS
SOLARIS THERAPEUTICS
Industry:
Biotechnology
Address:
Doylestown, Pennsylvania, United States
Country:
United States
Status:
Active
Total Funding:
0
Similar Organizations
Adriacell
Anti-tumor therapeutics
ImCure Therapeutics
ImCure Therapeutics
Investors List
BioAdvance
BioAdvance investment in Seed Round - Solaris Therapeutics
BioAdvance
BioAdvance investment in Seed Round - Solaris Therapeutics
BioAdvance
BioAdvance investment in Seed Round - Solaris Therapeutics
BioAdvance
BioAdvance investment in Seed Round - Solaris Therapeutics
More informations about "Solaris Therapeutics"
Solaris Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Last update 02 May 2024. Solaris Therapeutics, Inc. Private Company |See details»
Solaris Therapeutics | Doylestown, PA, USA Startup - Gust
Solaris develops drugs against the E3 ligase family of proteins, implicated in diseases across multiple therapeutic areas. Our lead, a novel oral antidiabetic shown to improve glucose control and insulin responsiveness, is 2 years and …See details»
Solaris Therapeutics - Funding, Financials, Valuation & Investors
Feb 10, 2012 Organization. Solaris Therapeutics . Connect to CRM . Save . Summary. Financials. People. Signals & News. Similar Companies. Highlights. Funding Rounds 4. …See details»
Solaris Pharma - Overview, News & Similar companies - ZoomInfo
View Solaris Pharma (www.solaris-pharma.com) location in New Jersey, United States , revenue, industry and description. ... Popular Searches solaris pharma Corp Solaris Pharma Solaris …See details»
Solaris Therapeutics - Updates, News, Events, Signals & Triggers
Solaris TherapeuticsSee details»
www.solaristherapeutics.com
Www.solaristherapeutics.comSee details»
Leveraging Predictive Dosing to Reduce Clinical Trial Risk
Feb 10, 2021 He was also the CEO of Solaris Therapeutics, a start-up developing small molecule inhibitors of E3 ligases, out of Columbia University. Prior to his time in pharma, Rich …See details»
Solaris Pharma - Company Profile - Tracxn
Dec 6, 2024 Solaris Pharma - Developer and Manufacturer of generic speciality dermatological drugs. Raised a total funding of $23.4M over 2 rounds from 1 investor. Founded by Lakshmi …See details»
Solaris Pharma Company Profile - Selligence
Solaris Pharma Corporation is uniquely poised to develop specialty dermatology products that have a relatively high barrier to entry due to manufacturing complexities and high-end clinical …See details»
Teva reports positive data for TEV-‘749 in …
May 9, 2024 The Phase III SOLARIS trial has revealed promising results for TEV-‘749, which Teva is developing as a once-monthly subcutaneous long-acting injection of olanzapine. The study met its primary endpoint, demonstrating …See details»
Teva Presents New Phase 3 Efficacy, Safety and ... - Financial Post
Sep 21, 2024 Additionally, SOLARIS (Period 1) and Phase 1 safety results demonstrated no incidence of post-injection delirium/sedation syndrome (PDSS) in participants taking TEV-‘749 …See details»
Scott Sellinger, MD, FACS - Solaris Health Partners
Dr. Scott Sellinger is Advisor, Advanced Prostate Cancer Therapeutics, for Solaris Health. He has been a partner at Southeastern Urological Center, now a division of Advanced Urology …See details»
Solaris Therapeutics - Crunchbase
Solaris TherapeuticsSee details»
Teva Presents New Research On Schizophrenia, Highlighting …
Nov 1, 2024 Teva Presents New Research On Schizophrenia, Highlighting SOLARIS Trial Results For TEV-749 . RTTNews. Nov. 1, 2024, 11:28 PMSee details»
Outlook Therapeutics® Streamlines Operations | Markets Insider
1 day ago ISELIN, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the …See details»
Teva Presents Latest Schizophrenia Treatment Research, Including …
Nov 1, 2024 SOLARIS study Period 1 is an 8-week, randomized, double-blind, placebo-controlled trial in patients aged 18-64 years diagnosed with schizophrenia, followed by an …See details»
Phase 3 SOLARIS Trial Demonstrates Potential of TEV-‘749 in …
May 9, 2024 The long-term safety of TEV-‘749 and incidence of PDSS are also being evaluated in the SOLARIS open-label study (period 2) with safety data topline readout expected in the …See details»
Solaris Vaccines - Crunchbase Company Profile & Funding
Solaris Vaccines is a biotechnology company that develops therapeutic vaccines for infectious diseases. The Solaris SolaVAX method uses riboflavin (vitamin B2) and UV light to rapidly and …See details»
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data …
Sep 21, 2024 Additionally, SOLARIS (Period 1) and Phase 1 safety results demonstrated no incidence of post-injection delirium/sedation syndrome (PDSS) in participants taking TEV-‘749 …See details»
Teva and Medincell Announce Positive Phase 3 Efficacy Results …
May 8, 2024 “These encouraging results from the efficacy portion of our Phase 3 SOLARIS trial demonstrate the potential of TEV-‘749 to be an effective long-acting treatment option for …See details»